Alan Hippe - Roche Holding Chief Financial and IT Officer
RHHBY Stock | USD 30.33 0.08 0.26% |
Executive
Dr. Alan Hippe was Member of the Corporationrationrate Executive Committee, Chief Financial Officer and Information Technology Officer at Roche Holding Ltd since April 1, 2011. Between 1993 and 1996 Dr. Hippe was Research Assistant and Teaching Assistant at the Universities of Mainz and Mannheim. In 1996 he joined AVECO Holding AG as Head of group controlling and IT systems. He served as Member of the Executive Board of Continental AG from 2002 to 2009. In April 2009 he was appointed Chief Financial Officer and Member of Executive Board of ThyssenKrupp AG. since 2011.
Age | 56 |
Tenure | 13 years |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Christopher Horan | Journey Medical Corp | 51 | |
Takayuki Yoshioka | Shionogi Co | N/A | |
Alycia Torres | Biofrontera | N/A | |
John Keller | Shionogi Co | 58 | |
Jackie Klecker | Lifecore Biomedical | N/A | |
Lauren Riker | Pacira Pharmaceuticals | 45 | |
Noriyuki Kishida | Shionogi Co | N/A | |
Gene Esq | Shuttle Pharmaceuticals | N/A | |
Takuko Sawada | Shionogi Co | 62 | |
Ian Clements | Journey Medical Corp | N/A | |
Samantha Widdicombe | Biofrontera | N/A | |
DO Ellis | Pacira Pharmaceuticals | 53 | |
Max Reinhardt | Pacira Pharmaceuticals | 53 | |
Esq III | Pacira Pharmaceuticals | 50 | |
Kara Morley | Lifecore Biomedical | N/A | |
Koji Hanasaki | Shionogi Co | N/A | |
Matt Augustson | Lifecore Biomedical | N/A | |
Miyuki Hiura | Shionogi Co | N/A | |
Joseph Benesch | Journey Medical Corp | 57 | |
Kristen JD | Pacira Pharmaceuticals | 50 | |
Takeshi Shiota | Shionogi Co | N/A |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
Bruno Eschli, Head Relations | ||
Silvia Ayyoubi, Head of Group HR | ||
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
Thomas Schinecker, Chief Diagnostics | ||
Beatrice Mauro, Non-Executive Director | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
Gottlieb Keller, General Counsel and Corporate Secretary | ||
Urs Jaisli, Chief Compliance Officer | ||
Daniel ODay, COO of Pharmaceuticals division | ||
Claudia Bockstiegel, G Counsel | ||
DeAnne Julius, Non-Executive Director | ||
Johannes MD, Head Devel | ||
Karl Mahler, Head of Investor Relations | ||
Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
Claudia Dyckerhoff, Non-Executive Director | ||
Fritz Gerber, Honorary Chairman of the Board | ||
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
Julie Brown, Non-Executive Director | ||
Richard Lifton, Non-Executive Director | ||
Paul Bulcke, Non-Executive Director | ||
Christoph Franz, Non-Executive Director | ||
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
Pascale Schmidt, Chief Officer | ||
Pius Baschera, Non-Executive Director | ||
Peter Voser, Non-Executive Director | ||
Bernard Poussot, Non-Executive Director | ||
John Bell, Non-Executive Director | ||
Andreas Oeri, Non-Executive Director | ||
Alan Hippe, Chief Financial and IT Officer | ||
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
F Hoffmann, IR Contact Officer | ||
Severin Schwan, CEO and Executive Director | ||
Anita Hauser, Non-Executive Director | ||
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 293.22 B | |||
Shares Outstanding | 6.4 B | |||
Shares Owned By Institutions | 1.27 % | |||
Price To Earning | 17.56 X | |||
Price To Book | 9.81 X | |||
Price To Sales | 3.99 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding Ltd. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |